BioMarin PharmaceuticalBMRN

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$13.4B

Price

$65.07

Today

−2.4%

Return YTD

+12.2%

Return 1Y

+14.9%

P/E

183.0

P/S

3.9

P/B

2.1

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Rare diseaseRare diseasesEnzyme therapyGene therapy

In the value chain

Products & services

Enzyme replacement therapies
Voxzogo (dwarfism)
Gene therapy (hemophilia)

Competitors

Sarepta Therapeutics
Ultragenyx
Vertex Pharmaceuticals

Risks

Rare-disease market
Gene therapy pricing

Supply chain

Supplies →

CencoraCOR

← Suppliers

Charles River LaboratoriesCRL

Full supply chain for BMRN →

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN BiogenBIIB Alnylam PharmaceuticalsALNY ModernaMRNA IncyteINCY

Compare BMRN

BMRN vs AMGN BMRN vs GILD BMRN vs VRTX BMRN vs REGN BMRN vs BIIB BMRN vs ALNY

See where BioMarin Pharmaceutical sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →